More and more research points to the effectiveness of new prefusion vaccines against the consequences of the respiratory syncytial virus (RSV). For example, there were recently two publications on RSV prefusion vaccines The New England Journal of Medicine.
RSV normally peaks in the winter season. The virus is a major cause of lower respiratory tract infections – which can be especially serious in babies and the elderly. In 2019, the virus caused an estimated half a million hospitalizations of people over 60 in developed countries. About 7% of them died…
The entire content of this article is only accessible to subscribers.
Read 3 articles FREE
Make an account. Free and without obligation.
I want 3x free
Always access to all NTvG publications?
Subscribe today!
Take the introductory subscription
€ 32.95 for 12 weeks!
I want to meet
Do you already have a subscription? login